Skip to main content
Equibles
PRLD logo

PRLD · Prelude Therapeutics Inc

Track PRLD — free

Use PRLD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRLD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.59 -0.08 (-1.71%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$366.30M
Shares
79.80M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.59 Open$4.72 Day$4.56–4.75 52W close$0.99–6.63 Avg vol 30d497K Short int3.6M · 4.5% float · 5.6d Short vol75% Last earningsMar 10, 2026 DataSep 2020–Sep 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.42M
Trailing 12 months
Net income (TTM)
−$60.49M
Trailing 12 months
Revenue growth YoY
+73.4%
Year over year
Operating margin
-300.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$151.76M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.5%
Year over year · more shares
Price change (1Y)
+292.4%
Trailing year
Short interest
4.5%
Latest settlement · 5.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +25%
above
Price vs 50-day avg −9%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 64%
mid-range
Momentum
relative strength
Strong
1-month return −14%
trailing
6-month return +54%
trailing
YTD return +58%
this year
Relative strength +36%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.50% of float · ▼ -5.8% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
77 holders — near 3-yr high, broad support
Squeeze score 48
elevated · 0–100
Fundamentals
Strong
Revenue growth +73%
Y/Y
EPS growth +23%
Y/Y
Free cash flow $-56.4M
Quant / Vol
risk profile
Very High
Volatility 200%
annualized · 1-yr
Max drawdown −70%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+25% Bullish
Price vs 50-day avg
−9% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
64% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.50% of float · ▼ -5.8% MoM · 5.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
77 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $5 · 64% Range high $7
vs 200-day avg +25% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PRLD
Prelude Therapeutics Inc
this stock
$366.30M +58.3% +73.4% — 4.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
77
% held
62.5%
Net QoQ
+19.1M sh
Top holder
ORBIMED ADVISORS LLC
Held Float
View
Held by Funds
Fund positions
57
View
Short & Settlement
Short Interest Falling
Shares short
3.6M
Days to cover
5.6d
Change
-223.0K sh
View
Short Volume
Short vol %
75%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
360
Value
$1.7K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
38.3%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$12.1M
Net income (FY)
$-99.5M
EPS diluted
$-1.29
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 10, 2026
This year
17
View
Exempt Offerings
Offering
$50.0M
Filed
Aug 28, 2020
View
Earnings & Events
Earnings Calls
Last call
Jun 10, 2026
View

Performance

5D 20D 120D MTD YTD
PRLD -12.6% -14.4% +53.5% -18.0% +58.3%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -11.4% -12.6% +35.7% -17.7% +46.2%
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 49 filings 49 filers Visit website Investor relations